Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 68

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 68
---
 public offering price of $2.80 per Unit after deducting commissions of approximately $312,900, and estimated offering expenses payable by us of $750,000.

In addition, we would receive up to an aggregate of approximately $4,172,000 million from the exercise of the warrants, assuming the exercise in full of all such warrants for cash.

We intend to use the net proceeds from this offering to fund our Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using our doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use the net proceeds of this offering to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin diseases. We will use any remaining net proceeds for general corporate purposes and working capital.

The amounts and timing of our actual expenditures will depend on numerous factors, the timing and success of any clinical trials and preclinical studies we may commence in the future, the timing of regulatory submissions, the status of our sales and marketing efforts, the amounts of proceeds actually raised in this offering and the amount of cash generated by our operations. Because we operate in a very dynamic and highly competitive industry, the actual use of proceeds may differ substantially from the ranges indicated above. Our management will have broad discretion to allocate the net proceeds from this offering.

<div align='center'>- 43 -

DILUTION</div>

If you invest in our Units in this offering, your interest will be immediately diluted to the extent of the difference between the public offering price per common share that is part of a Unit in this offering and the adjusted net tangible book value per common share after this offering. Dilution results from the fact that the public offering price per common share is substantially in excess of the net tangible book value per common share. As of September 30, 2024, we had a historical net tangible book value of $0.32 per common share after giving effect to the Share Consolidation. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of common shares outstanding on September 30, 2024.

After giving effect to the sale of Units in this offering at the public offering price of $2.80 per Unit after deducting the estimated commissions and estimated offering expenses, our as adjusted net tangible book value at September 30, 2024 would have been $0.54 per share. This represents an immediate increase in as adjusted net tangible book value